Article
Oncology
Xiaoxue Yin, Xingming Zhang, Xiuyi Pan, Junya Tan, Linmao Zheng, Qiao Zhou, Ni Chen
Summary: This study analyzed the morphological, immunophenotypic, and molecular changes in tumors with overlapping histological features of metanephric adenomas (MAs) and Wilms' tumors (WTs). The results showed that the molecular changes in these overlapping tumors were the same as those of typical MAs, suggesting that they should be classified as atypical MA. Atypical MA has different histological morphology and a higher Ki-67 index but shares common imaging characteristics, immunophenotype, and gene expression with typical MA. Patients with atypical MA usually have a good prognosis.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Jingp Gong, Aisheng Dong, Chengwei Shao
Summary: Metanephric adenoma is a rare benign renal tumor that can appear as a cold spot on imaging, mimicking renal cell carcinoma. This case highlights the importance of accurate imaging techniques in diagnosing such tumors.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Cell Biology
Xiao Teng, Zhen Chen, Lichen Zhang, Xiaodong Teng
Summary: This study aims to describe a distinct and rare histological subtype of pulmonary bronchiolar adenoma: bronchiolar adenoma with squamous metaplasia. Clinicopathological, immunohistochemical, and molecular characteristics of five cases were examined. The samples showed bilayered bronchiolar-type cells, sheet-like spindle-oval cells with squamous metaplasia in the stroma. Immunohistochemistry analysis revealed positive staining for TTF-1, Napsin A, P40, P63, and BRAF V600E. It is important to differentiate this subtype from pulmonary sclerosing pneumocytoma.
Article
Biology
Niccolo Lenci, Pierconti Francesco, Eros Scarciglia, Vincenzo Fiorentino, Mattia Schino, Giuseppe Palermo, Marco Racioppi, Pierfrancesco Bassi, Maurizio Martini
Summary: Metanephric adenoma (MA) is a rare benign renal tumor that can be challenging to diagnose, and sequencing analysis may be necessary for cases of MA with negativity for BRAF VE1 clone.
MEDICAL MOLECULAR MORPHOLOGY
(2021)
Article
Pathology
Pedram Argani, Satish K. Tickoo, Andres Matoso, Christine A. Pratilas, Rohit Mehra, Maria Tretiakova, Mathilde Sibony, Alan K. Meeker, Ming-Tseh Lin, Victor E. Reuter, Jonathan I. Epstein, Jeffrey Gagan, Doreen N. Palsgrove
Summary: The genetics of adult nephroblastoma is largely unknown, but some epithelial tumors with differentiated areas harbor targetable BRAF V600E mutations and appear to arise from metanephric adenomas. Other adult nephroblastomas often have genetic alterations found in pediatric cases, suggesting similarities in their pathogenesis.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2022)
Review
Oncology
Megha Puri, Kunal Gawri, Richa Dawar
Summary: Lung cancer is a leading cause of cancer-related deaths, with non-small cell lung cancer accounting for 85% of cases. The study of genetic alterations has led to targeted therapeutic interventions, including drugs targeting mutations in genes like KRAS, EGFR, BRAF, and ALK. This article summarizes BRAF mutations, available drug therapies, resistance mechanisms, the significance of profiling concurrent mutations, and the role of immune checkpoint inhibitors in BRAF-mutated non-small cell lung cancer.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Yuqian Fan, Jingjing Yu, Ming Zhao
Summary: Metanephric stromal tumor (MST) is a rare renal neoplasm that primarily affects pediatric patients, but can also occur in adults. Molecular detection of BRAF mutations can be a useful diagnostic tool to distinguish MST from other renal stromal tumors.
FRONTIERS IN ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Fatma Eldihimi, Cynthia Walsh, Rebecca M. Hibbert, Khalid Al Nasibi, Jana Sheinis Pickovsky, Nicola Schieda
Summary: A CT scoring system can be used to diagnose ccRCC among small solid renal masses and guide renal mass biopsy decisions in clinical practice.
EUROPEAN RADIOLOGY
(2023)
Article
Pathology
Sanjun Guo, Huan Qian, Hong Zhu, Yue Yang, Xudan Yang, Huajun Sun
Summary: This case report describes a rare renal tumor called metanephric stromal tumor (MST) in a 45-year-old woman. Genetic analysis revealed a mutation in the PDGFRA gene, but not the BRAF V600E mutation commonly found in pediatric MSTs. The patient had no recurrence or metastasis nine months after surgery and maintained normal blood pressure.
DIAGNOSTIC PATHOLOGY
(2023)
Review
Pharmacology & Pharmacy
Frank Aboubakar Nana, Sebahat Ocak
Summary: Osimertinib is now a standard first-line treatment for NSCLC with specific EGFR mutations, however, resistance mechanisms are inevitable. This study discusses acquired resistance mechanisms, specifically the BRAF V600 mutation, in EGFR-mutant NSCLC patients treated with Osimertinib in combination with dabrafenib and trametinib.
Article
Radiology, Nuclear Medicine & Medical Imaging
Khalid Al Nasibi, Jana Sheinis Pickovsky, Fatma Eldehimi, Trevor A. Flood, Luke T. Lavallee, Anne K. Tsampalieros, Nicola Schieda
Summary: This study developed a CT-based algorithm for diagnosing ccRCC among small solid renal masses. By evaluating the mass-to-cortex corticomedullary attenuation ratio and heterogeneity score, the algorithm can accurately diagnose ccRCC.
AMERICAN JOURNAL OF ROENTGENOLOGY
(2022)
Article
Oncology
Marcel Wiesweg, Cedric Preuss, Julia Roeper, Martin Metzenmacher, Wilfried Eberhardt, Ursula Stropiep, Katrin Wedeken, Henning Reis, Thomas Herold, Kaid Darwiche, Clemens Aigner, Martin Stuschke, Hans-Ulrich Schildhaus, Kurt W. Schmid, Markus Falk, Lukas Heukamp, Markus Tiemann, Frank Griesinger, Martin Schuler
Summary: BRAF mutations in NSCLC patients have different subtypes, with V600E being the most common, but a majority of patients harbor other BRAF mutations of functional classes II/III. Despite the poor prognosis of BRAF-mutated NSCLC, they exhibit high susceptibility to immune checkpoint inhibitors compared to other tractable driver mutations in NSCLC.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Public, Environmental & Occupational Health
Alok Anshu, Anil Kumar
Summary: Metanephric adenoma is a rare benign mass that resembles malignant renal cell carcinoma in clinical presentation and radiological features, making it challenging to diagnose. Only 200 cases have been reported worldwide, and there are no reliable clinical and radiological criteria for accurate prediction. Accurate differentiation from other malignant renal masses is crucial for appropriate post-operative therapy.
Review
Oncology
Xianwen Hu, Wenxin Li, Jie Bai, Dandan Li, Pan Wang, Jiong Cai
Summary: This study reported a case of a 5-year-old girl who was found to have a mass in the right kidney during a routine physical examination. Imaging tests revealed high-density calcifications in the mass, and postoperative pathology confirmed it to be a metanephric adenoma (MA). The study suggests that MA should be considered as one of the imaging differential diagnoses of fat-poor angiomyolipoma, renal carcinoma, and oncocytoma.
Article
Endocrinology & Metabolism
Jiajia Tang, Shitao Jiang, Jiaojiao Ma, Xuehua Xi, Huilin Li, Liangkai Wang, Bo Zhang
Summary: This study established an ultrasound radiomics nomogram for assessing BRAF status in PTMC patients, identifying radiomics score, composition, and aspect ratio as independent predictive factors of BRAF status. The radiomics nomogram demonstrated better predictive performance compared to the conventional ultrasound model.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Vishal Navani, J. Connor Wells, Devon J. Boyne, Winson Y. Cheung, Darren M. Brenner, Bradley A. McGregor, Chris Labaki, Andrew L. Schmidt, Rana R. McKay, Luis Meza, Sumanta K. Pal, Frede Donskov, Benoit Beuselinck, Maxwell Otiato, Lisa Ludwig, Thomas Powles, Bernadett E. Szabados, Toni K. Choueiri, Daniel Y. C. Heng
Summary: Limited data exists regarding the efficacy of cabozantinib following contemporary first line therapy options in advanced kidney cancer. A real world database analysis of 346 patients revealed clinically meaningful activity of second line cabozantinib after all evaluated contemporary first line therapies, including immune checkpoint blockade combination approaches.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Akram M. Shayeb, Hannah Dzimitrowicz McManus, Danielle Urman, Chinmay Jani, Tian Zhang, Nazli Dizman, Luis Meza, Akhilesh Sivakumar, Chun L. Gan, Pedro Barata, Mehmet A. Bilen, Xin Gao, Daniel Heng, Sumanta Pal, Ravi Narra, Deepak Kilari, Marina D. Kaymakcalan, Bradley McGregor, Toni K. Choueiri, Rana R. McKay
Summary: In this retrospective multicenter study, the safety of cabozantinib with different anticoagulants in patients with advanced RCC was investigated. The study found that DOACs appear to be safe for VTE treatment in patients on cabozantinib without increasing the risk of major bleeding events. Optimized anticoagulation management remains vital in clinical practice.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Urology & Nephrology
Ziad Bakouny, Talal El Zarif, Shaan Dudani, J. Connor Wells, Chun Loo Gan, Frede Donskov, Julia Shapiro, Ian D. Davis, Francis Parnis, Praful Ravi, John A. Steinharter, Neeraj Agarwal, Ajjai Alva, Lori Wood, Anil Kapoor, Jose M. Ruiz Morales, Christian Kollmannsberger, Benoit Beuselinck, Wanling Xie, Daniel Y. C. Heng, Toni K. Choueiri
Summary: This study found that upfront cytoreductive nephrectomy (CN) is associated with improved clinical outcomes and overall survival in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors or targeted therapy. This suggests that upfront CN still has a significant role for selected patients in the era of immune checkpoint inhibitors.
Article
Oncology
Ziad Bakouny, Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati, Chih-Yuan Hsu, Saif Alimohamed, Babar Bashir, Stephanie Berg, Mehmet A. Bilen, Daniel Bowles, Cecilia Castellano, Aakash Desai, Arielle Elkrief, Omar E. Eton, Leslie A. Fecher, Daniel Flora, Matthew D. Galsky, Margaret E. Gatti-Mays, Alicia Gesenhues, Michael J. Glover, Dharmesh Gopalakrishnan, Shilpa Gupta, Thorvardur R. Halfdanarson, Brandon Hayes-Lattin, Mohamed Hendawi, Emily Hsu, Clara Hwang, Roman Jandarov, Chinmay Jani, Douglas B. Johnson, Monika Joshi, Hina Khan, Shaheer A. Khan, Natalie Knox, Vadim S. Koshkin, Amit A. Kulkarni, Daniel H. Kwon, Sara Matar, Rana R. McKay, Sanjay Mishra, Feras A. Moria, Amanda Nizam, Nora L. Nock, Taylor K. Nonato, Justin Panasci, Lauren Pomerantz, Andrew J. Portuguese, Destie Provenzano, Matthew Puc, Yuan J. Rao, Terence D. Rhodes, Gregory J. Riely, Jacob J. Ripp, Andrea Rivera, Erika Ruiz-Garcia, Andrew L. Schmidt, Adam J. Schoenfeld, Gary K. Schwartz, Sumit A. Shah, Justin Shaya, Suki Subbiah, Lisa M. Tachiki, Matthew D. Tucker, Melissa Valdez-Reyes, Lisa B. Weissmann, Michael T. Wotman, Elizabeth M. Wulff-Burchfield, Zhuoer Xie, Yuanchu James Yang, Michael A. Thompson, Dimpy P. Shah, Jeremy L. Warner, Yu Shyr, Toni K. Choueiri, Trisha M. Wise-Draper
Summary: This cohort study found that systemic anticancer therapies, especially IO, in the context of baseline immunosuppression, were associated with severe clinical outcomes and the development of cytokine storm in patients with cancer and COVID-19.
Article
Oncology
Karl H. Tully, Sebastian Berg, Marco Paciotti, Florian Janisch, Stephen W. Reese, Joachim Noldus, Shahrokh F. Shariat, Toni Choueiri, Guido Mueller, Bradley McGregor, Steven L. Chang, Quoc-Dien Trinh, Matthew Mossanen
Summary: This retrospective study using the National Cancer DataBase found that the unfavorable median overall survival in patients diagnosed with renal cell carcinoma with sarcomatoid differentiation was mainly caused by a high number of cases diagnosed with late-stage disease. Additionally, surgical therapy was associated with favorable overall survival across all stages. This study supports the notion that surgical therapy provides a survival benefit in patients with sRCC.
CLINICAL GENITOURINARY CANCER
(2023)
Editorial Material
Urology & Nephrology
Matthew S. Ernst, Vishal Navani, J. Connor Wells, Frede Donskov, Naveen Basappa, Chris Labaki, Sumanta K. Pal, Luis Meza, Lori A. Wood, D. Scott Ernst, Bernadett Szabados, Rana R. McKay, Francis Parnis, Cristina Suarez, Takeshi Yuasa, Aly-Khan Lalani, Ajjai Alva, Georg A. Bjarnason, Toni K. Choueiri, Daniel Y. C. Heng
Summary: This study establishes real-world clinical benchmarks for immune-oncology (IO) and vascular endothelial growth factor targeted therapies (VEGF-TT) combination treatments in metastatic renal cell carcinoma (mRCC) patients, based on the International mRCC Database Consortium (IMDC) criteria.
Article
Oncology
Chris Labaki, Toni K. Choueiri
Summary: The first phase III trial of perioperative immune-checkpoint inhibitor therapy for high-risk renal cell carcinoma showed promising results, leading to regulatory approvals. However, subsequent trials did not demonstrate similar benefits, and the unique design of each trial might explain some of the patterns identified.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Oncology
Omar Alhalabi, Jonathan Thouvenin, Sylvie Negrier, Yann-Alexandre Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew W. Hahn, Mehmet Asim Bilen, Pavlos Msaouel, Toni K. Choueiri, Srinivas R. Viswanathan, Kanishka Sircar, Laurence Albiges, Gabriel G. Malouf, Nizar M. Tannir
Summary: This article evaluates the clinical activity of immune checkpoint therapy combinations with or without VEGF targeted therapy in patients with translocation renal cell carcinoma. The study found that the combination of immune checkpoint therapy and VEGF targeted therapy showed some efficacy in translocation renal cell carcinoma. However, due to the heterogeneity of this type of cancer, further understanding of its biological mechanisms is necessary to develop more effective treatments.
Article
Multidisciplinary Sciences
Amin H. Nassar, Sarah Abou Alaiwi, Sylvan C. Baca, Elio Adib, Rosario I. Corona, Ji-Heui Seo, Marcos A. S. Fonseca, Sandor Spisak, Talal El Zarif, Viktoria Tisza, David A. Braun, Heng Du, Monica He, Abdallah Flaifel, Michel Alchoueiry, Thomas Denize, Sayed G. Matar, Andres Acosta, Sachet Shukla, Yue Hou, John Steinharter, Gabrielle Bouchard, Jacob E. Berchuck, Edward O'Connor, Connor Bell, Pier Vitale Nuzzo, Gwo-Shu Mary Lee, Sabina Signoretti, Michelle S. Hirsch, Mark Pomerantz, Elizabeth Henske, Alexander Gusev, Kate Lawrenson, Toni K. Choueiri, David J. Kwiatkowski, Matthew L. Freedman
Summary: This study explores the epigenome of renal cell carcinoma (RCC) and identifies histology-specific master transcription factors (MTFs). Integration of RCC GWAS risk SNPs with epigenomic data reveals enrichment of risk variants in allelically-imbalanced peaks.
NATURE COMMUNICATIONS
(2023)
Article
Engineering, Environmental
Grishma Desai, Gurumurthy Ramachandran, Emanuel Goldman, William Esposito, Antony Galione, Altaf Lal, Toni K. Choueiri, Andre Fay, William Jordan, Donald W. Schaffner, Jack Caravanos, Etienne Grignard, Gediminas Mainelis
Summary: Grignard Pure (GP), a blend of triethylene glycol (TEG) and inert ingredients, is an effective antimicrobial treatment for air. It has received approval from the US EPA and can rapidly reduce viable MS2 bacteriophage concentration. The study also discusses related efficacy experiments and the safety of TEG.
ENVIRONMENTAL SCIENCE & TECHNOLOGY
(2023)
Article
Oncology
Cristiane Decat Bergerot, Jasnoor Malhotra, Paulo Bergerot, Errol J. Philip, Daniela Castro, JoAnn Hsu, Augusto Cesar de Andrade Mota, Andressa Cardoso de Azeredo, Joao Nunest de MatosNeto, Thomas Hutson, Viktor Gruenwald, Axel Bex, Sarah P. Psutka, Brian Rini, Elizabeth R. Plimack, Viraj Master, Laurence Albiges, Toni K. Choueiri, Sumanta Pal, Thomas Powles
Summary: This study investigated the perceived relevance of items in the FKSI-19 questionnaire among patients with metastatic renal cell carcinoma. The results showed that patients found fatigue, lack of energy, and worry about disease progression to be the most relevant items, while blood in urine, fevers, and lack of appetite were considered least relevant. The study also identified other themes related to symptoms, ability to live independently, treatment effectiveness, family, spirituality, and financial toxicity.
Article
Oncology
David-Dan Nguyen, Muhieddine Labban, Logan Briggs, Christopher J. D. Wallis, Alexander P. Cole, Stuart R. Lipsitz, Hari S. Iyer, Timothy R. Rebbeck, Joel S. Weissman, Toni K. Choueiri, Quoc-Dien Trinh
Summary: This study aims to investigate the role of healthcare facilities in driving socioeconomic and racial disparities in prostate cancer. The study found that men receiving care at hospital systems serving health disparity populations had lower rates of guideline-concordant treatment, delayed treatment initiation, and worse overall survival. Additionally, African American men treated at these healthcare facilities had worse outcomes.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Cell Biology
Julie Stein Deutsch, Evan J. Lipson, Ludmila Danilova, Suzanne L. Topalian, Jaroslaw Jedrych, Ezra Baraban, Yasser Ged, Nirmish Singla, Toni K. Choueiri, Saurabh Gupta, Robert J. Motzer, David McDermott, Sabina Signoretti, Michael Atkins, Janis M. Taube
Summary: H&E scoring of tumor-infiltrating immune cells (TILplus) using light microscopy in pre-treatment tumor specimens is associated with improved overall survival in patients with clear cell renal cell carcinoma.
CELL REPORTS MEDICINE
(2023)
Article
Oncology
Toni K. Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler, Naveen S. Basappa, Maria Jose Mendez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melichar, Thomas Hutson, Carlos Alemany, Bradley McGregor, Thomas Powles, Viktor Gruenwald, Boris Alekseev, Sun Young Rha, Evgeny Kopyltsov, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C. Goh, Michael Staehler, Jaime R. Merchan, Ran Xie, Rodolfo F. Perini, Kalgi Mody, Jodi McKenzie, Camillo Porta
Summary: In patients with advanced renal cell carcinoma, lenvatinib plus pembrolizumab showed significant improvements in progression-free survival and overall survival compared to sunitinib, as demonstrated in a 7-month additional follow-up.
Letter
Oncology
Thomas Powles, Joseph E. Burgents, Lei Xu, Toni K. Choueiri